Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Domenica LorussoMarie-Ange Mouret-ReynierPhilipp HarterClaire CropetCristina CaballeroPia Wolfrum-RistauToyomi SatohIgnace VergoteGabriella ParmaTrine J NøttrupCoriolan LebretonPeter A FaschingCarmela PisanoLuis MansoHugues BourgeoisIngo RunnebaumClaudio ZamagniAnne-Claire Hardy-BessardAndreas SchnelzerMichel FabbroBarbara SchmalfeldtDominique BertonAntje BelauJean-Pierre LotzMartina Gropp-MeierLaurence GladieffHans-Joachim LückSophie Abadie-LacourtoisieEric Pujade-LauraineIsabelle L Ray-CoquardPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
analysis indicates that in patients with newly diagnosed advanced HRD-positive ovarian cancer, maintenance olaparib plus bevacizumab should not be limited to those considered at higher risk of disease progression. Five-year progression-free survival rates support long-term remission and suggest an increased potential for cure with particular benefit suggested in lower-risk HRD-positive patients.